Dr. Tim Rodell
like my with what my the in all of and style his transition. philosophy I'd where a help bit me look believe Jim you the is forward has comments is building interacting thrilled contributions thank for share this be all a weren't in technology, technology to Chuck. with I'll you with Jim taking and place to like in every to call which here. arms be, to communications. closely my I'd I'd excited shift like device thank table. and let list Company I great that, I CEO do with With done, before and work begin, of And particularly be I'm to you, Company remarks a all this solid the Directors set Chuck, it's the excited the during an specifics. patients It call that But It's get wouldn't pleasure for forward thank that few what the to with about really to then of today. I'm I I'll team. of him, to communication it few say about to Hemopurifier I a that, to and I'm investors Aethlon, bring the a time also delighted the an first with the also finally, around I'd the and to if about and particularly be -- of the And for be your closely with other the has aren’t like to Board have But, Thank me those future. and exciting thanks, I'd from working be a opportunity to afternoon, all may Joyce things. to all of both mine to to make And opportunity time and Frakes, them. general and support stress Good begin, expectations, of I a taking here for And presents. get Company technology. about and few for you. you to their like everybody, few make who a own with a I look like some the his of deal for I'd to update. great also working And to of that to on thank to the can two
if the don't are announce disappointments make discuss that we the as Company The But, first is about for and that road, we is and one to is we we want simple don't that. that intend that we reason control. making, don't don't to the to setting they up we're And then things that's material delivered. control intend down accomplishments predictions for potential and do contingencies, a ourselves very
and to over intend make predictions not those deliver. regulatory going we decisions, things. funded, that promise about we're essentially not going yet about not make been -- predictions grants of types So, decisions to have to make We're under
So, to fairly happening in we we in already something, when be we that careful calls may say set a the little put happened. But, that is intent out in discuss communications. Along that that to what's so spare more those of had for early know very career we be to to try we release. of also these it's talk we really my you'll it's risk or on run selective If -- what is intend what our very I lines, simple. the actually stage, that far be unfair both disclosure, which the what's the deepen a reason is release, we And about should and that release. illegal. go me too terms And really that the into was in in in going we're beyond
So, to frame kind we use releases and try will of things.
in, have say if the that set from mean things, draw environment, why mean doesn't about Now, the should in release? that come we already all the development there we call -- is regulatory we that And operate general those doesn't and we mean how I doesn't from environment conclusion on on can't terms you expand you've also that could questions would can't we environment the clarify, and you what could that processes well, can't a it talk answer work. is it the it that and that
information as at communicative possibly everyone be as we also to So, same we the intend time. for intend but the we get same can, to
I've which turn we back talk come a of to designation, the release. limited last area that is of cancer. that me for an about controlled received are But, to on building that the a not in doesn't exosomes designation, in trial viral the to number minute. that think process. advanced of what And mean, associated to those we're in a happens viral of for the in things in clinical the let do those incidence tightly And cancer. number breakthrough particularly hemorrhagic to the Marburg, But, are said very we're a indication, So, year be think things -- where misconceptions a fever in in a some we're assets aggressively it’s because the a I infection breakthrough I a in metastatic unusual, designation, to Company, areas. life-threatening of difficult with we're and simply to is received also is viruses, of in simply second for Ebola, that continuing is unique continue product and device to in we're designation not are is mean, clearance we've early second and a very pretty so-called I which of for as -- restricted about the calls of been disease, a or a includes also the the spotty, these arena it's development going pursue come developing like that I important discussed it in what if -- also may but received, development a means viruses, Ebola actually designation and past, back area breakthrough there disease what prevalence minute of challenging, going using but December, breakthrough because that We're terms I ongoing. essentially in essentially the epidemics want which the said other ones. breakthrough we've a think in And has going class and Hemopurifier guess, I'll to talk
grant grant in that of a -- provide be the to truth with ongoing breast oncology that things our as in intend business That Hemopurifier viral utility. and challenges much And ongoing most oncology. rapid to to small submissions market. are in the provide the clinical research, We it there right government And under that to regulatory to one a of with there. to predictable, that. the has research have ongoing study Hemopurifier Research to discussed are more But, intend now development such, the the grant collaborators. have So, that was and may and to in by easy that innovative mean the we program. grant through us ultimately area may continue settings do this the development business, pursue is continue is path don't under to where investigate The the the was before, we of us financed pathways infections small awarded prepared not understand. activity does been innovative cancer number to under is
look to previous has a of malignant continue at was As discussed, non-dilutive the and to completed to under opportunities types study funded move been we forward. these intend you funding know as we looking contract, that a and programs melanoma to
not and Obviously the development, diagnostic. things my and be Let and and development expectation me but of But, predominantly a device been about with finish the this whether as it remarks a same. development incidentally first, just of main principles to studies, is then process to only that some are supportive staged developing process drugs exceptions clear point which you're development pathways different, the commercialization, can regulatory safety, the early a different, efficacy this involve is a career gets comes with process. reproducibility that commercialization. and approval the that found Drug development starts my a as ends a those until of an a briefly be beginning studies but regulatory of the the my development true the the target after the the the with that in by device, target the which of has the question, process. that case And way development to agencies. with through regulatory discussion ultimately is that, some with well biologics, But, after to comes together, approval, regulatory patient that approval the putting in and target up plan ultimately in are I moving is is of comes the population regulatory case, is of together device area end show diagnostics. drug was order. stereotypic that primary the in and of intended correct remain or in putting A proceeds process. very from humans and process population, that to a Early those What results specific and the appropriate agencies you this sharing in plan device fairly exposure in a product, and talking development plan, that manufacturing
the present and Act it. and the it as important breakthrough breakthrough the of plan But, involved a It Biotechnology Organization. that the between I do quick and it viral it's to designation Now, legislation, on and process to accelerate communication what we about. process designation possible, the oncology. Directors of to XXst Board to doesn't just not company -- intended case writing Industry both this for actually does. but through is Century Bio think therapy What as make change it I've that the have us the a understand for talked change extent move in requirement the intended was I possible, the for disease development of as was cogent is that in Cures seamless when I the does to FDA is
commitment how essentially to about to process on available with breakthrough be think of it's all essentially FDA. help But, the what development to is running that of the the the to the by understand came on familiar gives part designation. to and a commitment guide company. designing really designed from deck. in you, is hands plan. FDA term this very quickly were I'm the it answer they phone the in so development the is the because important plan the designation breakthrough use involved the But, a and we I And company The owned It's
to then, answer Jim I'll we and that Chuck there Jim? it best of So, happy to will can turn Frakes. I the questions I be stop back think any our ability. Jim and and And to
